179 related articles for article (PubMed ID: 23911703)
1. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.
Parikh SA; Rabe KG; Kay NE; Call TG; Ding W; Schwager SM; Bowen DA; Conte M; Jelinek DF; Slager SL; Shanafelt TD
Haematologica; 2014 Jan; 99(1):140-7. PubMed ID: 23911703
[TBL] [Abstract][Full Text] [Related]
2. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.
Shanafelt TD; Rabe KG; Kay NE; Zent CS; Jelinek DF; Reinalda MS; Schwager SM; Bowen DA; Slager SL; Hanson CA; Call TG
Cancer; 2010 Oct; 116(20):4777-87. PubMed ID: 20578179
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Royo C; Navarro A; Pinyol M; Rozman M; Pereira A; Villamor N; Aymerich M; López C; Carrió A; Montserrat E
Haematologica; 2014 Oct; 99(10):1599-604. PubMed ID: 24972773
[TBL] [Abstract][Full Text] [Related]
4. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.
Parikh SA; Leis JF; Chaffee KG; Call TG; Hanson CA; Ding W; Chanan-Khan AA; Bowen D; Conte M; Schwager S; Slager SL; Van Dyke DL; Jelinek DF; Kay NE; Shanafelt TD
Cancer; 2015 Sep; 121(17):2883-91. PubMed ID: 25931291
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.
Garces S; Khoury JD; Kanagal-Shamanna R; Salem A; Wang SA; Ok CY; Hu S; Patel KP; Routbort MJ; Luthra R; Tang G; Schlette EJ; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Hum Pathol; 2018 Dec; 82():215-231. PubMed ID: 30086334
[TBL] [Abstract][Full Text] [Related]
6. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
[TBL] [Abstract][Full Text] [Related]
7. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
[TBL] [Abstract][Full Text] [Related]
8. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia].
Szerafin L; Jakó J; Riskó F
Orv Hetil; 2015 Apr; 156(15):592-7. PubMed ID: 25845318
[TBL] [Abstract][Full Text] [Related]
10. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of patients' sex in chronic lymphocytic leukemia.
Catovsky D; Wade R; Else M
Haematologica; 2014 Jun; 99(6):1088-94. PubMed ID: 24658818
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
13. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
Del Poeta G; Del Principe MI; Zucchetto A; Luciano F; Buccisano F; Rossi FM; Bruno A; Biagi A; Bulian P; Maurillo L; Neri B; Bomben R; Simotti C; Coletta AM; Dal Bo M; de Fabritiis P; Venditti A; Gattei V; Amadori S
Haematologica; 2012 Feb; 97(2):279-87. PubMed ID: 21993667
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and risk stratification in chronic lymphocytic leukemia.
Parikh SA; Shanafelt TD
Semin Oncol; 2016 Apr; 43(2):233-40. PubMed ID: 27040701
[TBL] [Abstract][Full Text] [Related]
15. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study.
Dhodapkar M; Tefferi A; Su J; Phyliky RL
Leukemia; 1993 Aug; 7(8):1232-5. PubMed ID: 8350623
[TBL] [Abstract][Full Text] [Related]
16. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of clinical and biological prognostic factors at diagnosis in patients with early stage B-cell chronic lymphocytic leukemia.
Oliveira AC; de la Banda E; Domingo-Domenech E; Encuentra M; Mercadal S; Domingo A; Alonso E; Espinet B; Grau J; De Sevilla AF; Gonzalez-Barca E
Leuk Lymphoma; 2011 Mar; 52(3):429-35. PubMed ID: 21323523
[TBL] [Abstract][Full Text] [Related]
20. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death.
Andersen MA; Vojdeman FJ; Andersen MK; Brown Pde N; Geisler CH; Weis Bjerrum O; Niemann CU
Leuk Lymphoma; 2016 Jul; 57(7):1592-9. PubMed ID: 26850493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
